Merus NV Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

30 Dec 2025

MRUS

SCHEDULE: Genmab Completes Merus N.V. Acquisition, Delists Shares

Genmab A/S and its subsidiary have successfully completed the tender offer and subsequent merger to acquire all outstanding shares of Merus N.V., leading to its delisting from Nasdaq.

19 Dec 2025

MRUS

Merus NV

SCHEDULE: Genmab Secures 94.8% of Merus N.V. in $97/Share Tender Offer

Genmab A/S has successfully acquired a 94.8% stake in Merus N.V. through a tender offer priced at $97.00 per common share, moving towards full control and delisting.